Abstract Number: 2828 • 2018 ACR/ARHP Annual Meeting
Utility of Fecal Calprotectin Levels for the Diagnosis of Inflammatory Bowel Disease in Patients with Spondylorarthritis
Background/Purpose: It is estimated that between 5 and 10% of patients with spondyloarthritis (SpA) are associated with inflammatory bowel disease (IBD).The purpose of our study…Abstract Number: 2829 • 2018 ACR/ARHP Annual Meeting
The Response to TNF-Blockers Treatment of Spa Patients Is Influenced By the Interplay between HLA-B27 and Gut Microbiota Composition at Baseline
Background/Purpose: The response to TNF-blockers in axial spondyloarthritis (AxSpA) is at least partially influenced by HLA-B27 through a still poorly understood mechanism. Given that HLA-B27…Abstract Number: 2830 • 2018 ACR/ARHP Annual Meeting
Synovitis in Psoriatic Arthritis and Seronegative Rheumatoid Arthritis: Differential Histological Features
Background/Purpose: To identify synovial tissue (ST) biomarkers differentially expressed in Psoriatic Arthritis (PsA) and seronegative Rheumatoid Arthritis (Abneg RA) and test their predictive value of…Abstract Number: 2831 • 2018 ACR/ARHP Annual Meeting
High Need for Anti-TNF Therapy after Withdrawal Strategy in Early Peripheral Spondyloarthritis
Background/Purpose: Treatment with TNFi in early stages of peripheral Spondyloarthritis (pSpA) results in higher rates of clinical remission, compared to treatment in more longstanding disease.…Abstract Number: 2832 • 2018 ACR/ARHP Annual Meeting
Multiple Subpopulations of Peripheral Lymphocytes Were Absolutely Decreased in SLE Patients with Infection and Restored By Low-Dose IL-2
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by disturbed cellular and humoral immune responses. Dysregulations of intrinsic or adaptive immune system…Abstract Number: 2833 • 2018 ACR/ARHP Annual Meeting
Complement Activation Is a Feature of Diseases in the Lupus Spectrum
Background/Purpose: We showed previously that complement activation - cell-bound complement activation products (CB-CAPS) or multi-analyte assay panel (MAP) - is a sensitive and specific biomarker…Abstract Number: 2834 • 2018 ACR/ARHP Annual Meeting
The Presence of Anti-Rituximab Antibodies Predicts Infusion-Related Reactions in Patients with Systemic Lupus Erythematosus
Background/Purpose: Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody that is commonly used in the treatment of severe and refractory SLE. Although generally well…Abstract Number: 2835 • 2018 ACR/ARHP Annual Meeting
Association between Changes in Gene Signature Expression and Disease Activity in Systemic Lupus Erythematosus
Background/Purpose: We assessed the stability of BAFF, interferon, plasma cell and LDG neutrophil gene expression signatures over time, and whether changes in gene expression coincided…Abstract Number: 2836 • 2018 ACR/ARHP Annual Meeting
Measurement of Interferon Alpha Expression Using Multiple Methodologies Identifies a Signature in a Subgroup of Connective Tissue Disease Patients with Haematological Abnormalities
Background/Purpose: Interferon alpha (IFNα) is an inflammatory cytokine implicated in the development and persistence of autoimmunity. Although IFNα expression is increased in a subgroup of…Abstract Number: 2837 • 2018 ACR/ARHP Annual Meeting
Diminished STAT-3 Phosphorylation and Associated Cell Pathways Characterize MMF-Treated Systemic Lupus Erythematosus Patients
Background/Purpose: Mycophenolate mofetil (MMF) is a commonly used medication to treat major organ involvement in SLE, specifically in patients with lupus nephritis. The safety and…Abstract Number: 2838 • 2018 ACR/ARHP Annual Meeting
Comorbid Vasculitis Among Patients in a National Primary Immunodeficiency Database
Background/Purpose: Vasculitis has been reported in patients with various forms of primary immunodeficiency (PID) in case reports in the literature. The goal of this study…Abstract Number: 2839 • 2018 ACR/ARHP Annual Meeting
Microrna Expression in the Vasculitic Skin Lesions of Adult Patients with IgA Vasculitis
Background/Purpose: IgA vasculitis (IgAV) represents a common systemic vasculitis in paediatric and adult population. Our current knowledge of disease pathogenesis is still very limited and…Abstract Number: 2840 • 2018 ACR/ARHP Annual Meeting
MiR-125-b Is a Promising Biomarker for Giant Cell Arteritis in Patients with Negative Temporal Artery Biopsy Examination
Background/Purpose: Giant cell arteritis (GCA) is a systemic vasculitis of large- and medium-sized arteries, diagnosed either with a temporal artery biopsy (TAB) histology or by…Abstract Number: 2841 • 2018 ACR/ARHP Annual Meeting
Apremilast for Behçet’s Syndrome: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study in a Japanese Subgroup
Background/Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in a global, phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with Behçet’s syndrome and…Abstract Number: 2842 • 2018 ACR/ARHP Annual Meeting
Does Leflunomide Have a Role in Giant Cell Arteritis?
Background/Purpose: Glucocorticoids have been the mainstay treatment of giant cell arteritis (GCA) for decades. Recently, tocilizumab has been proven to be an effective alternative to…
ACR Meeting Abstracts